Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market. Leveraging its established dominance in diabetes care and insulin leadership, the company seeks to accelerate adoption of its GLP-1 therapy, positioning it against rivals like Eli Lilly.

See Full Page